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Abstract 
Perlecan, or heparan sulfate proteoglycan 2 (HSPG2), is a ubiquitous heparan sulfate proteoglycan that 
has major roles in tissue and organ development and wound healing by orchestrating the binding and 
signaling of mitogens and morphogens to cells in a temporal and dynamic fashion. In this review, its 
roles in fibrosis are reviewed by drawing upon evidence from tissue and organ systems that undergo 
fibrosis as a result of an uncontrolled response to either inflammation or traumatic cellular injury leading 
to an over production of a collagen-rich extracellular matrix. This review focuses on examples of fibrosis 
that occurs in lung, liver, kidney, skin, kidney, neural tissues and blood vessels and its link to the 
expression of perlecan in that particular organ system.   
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1. Introduction 
Fibrosis is a complex and finely tuned process that occurs in response to either inflammation, 
traumatic cellular injury or as a result of unknown or congenital issues affecting the structure of the 
extracellular matrix (ECM). Fibrosis is generally associated with pathological changes where significant 
increases in the expression and assembly of the ECM, notably the collagen content of the tissues. This 
has significant longer term impacts on the structural and functional properties of the tissues that may 
lead to impairment and failure of that organ. While the primary attributes seen in these diseases lie in 
the over-production of collagen in the tissues, changes in perlecan, also known as heparan sulfate 
proteoglycan 2 (HSPG2), levels also occur [1-3].  
It is now well accepted that fibrosis is not a static event, but a dynamic process involving several 
phases that are also common to the wound healing response. Initially, an influx of inflammatory cells 
are seen that become activated resulting in the downstream activation of tissue resident ECM secreting 
cells followed by a significant change in the structure of ECM from an increased synthesis and 
decreased proteolytic turnover, further immune cell infiltration and delayed apoptosis [4, 5]. Many of 
these phases involve heparin-binding growth factors, cytokines and chemokines suggesting that 
heparan sulfate (HS) proteoglycans play important roles in this process [6]. Despite the range of 
biological activities of HS, there are only a few HS proteoglycans present in the ECM including perlecan, 
collagen type XVIII and agrin [7]. The abundance of perlecan in basement membranes and connective 
tissues that exhibit fibrosis [7, 8] as well as the key roles that it plays in many tissues suggests that it 
may play important roles in fibrosis. Recent evidence that will be reviewed in the following sections 
supports the hypothesis that perlecan plays key roles in the regulation of fibrogenesis. 
 
1.2 Overview of perlecan 
 
1.2.1 Structure of perlecan 
Perlecan is a ubiquitous HS proteoglycan synthesized by most cells and present in most pericellular 
and extracellular matrices and is recognized as an essential component of basement membranes [7, 
9]. Perlecan has also been localized to connective tissues and is produced by leukocytes [10]. The 
protein core of human perlecan is 460 kDa and composed of five distinct domains with 
glycosaminoglycan attachment sites located in both the N- and C-terminal domains (Fig. 1). Perlecan 
exerts tissue-specific activities through its glycosaminoglycan chains as the structure of these depends 
on the context and cell source. Typically, the three glycosaminoglycan attachment sites in domain I are 
decorated with HS, which has been shown for endothelial cell derived perlecan [11]. Perlecan may also 
be decorated with chondroitin and/or keratan sulfate (CS and KS respectively) in addition to HS as has 
been demonstrated for smooth muscle and epithelial cell derived perlecan [12-14] and these may also 
utilize the glycosaminoglycan attachment site in domain V [15]. There are many biological functions 
ascribed to perlecan including playing central roles in regulating the assembly of the ECM and the 
binding and presentation of growth factors to cells [16].  
 
1.2.2 Functions of the glycosaminoglycan chains 
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The HS chains that decorate perlecan electrostatically interact with growth factors enabling their 
storage in the ECM, protection from proteolytic degradation and potentiation of their activity when bound 
to their cognate receptors [17, 18]. The HS chains of perlecan, bind and modulate the signaling of 
fibroblast growth factors (FGF) 1, 2 and 18 [13, 14, 19, 20] and also bind to other heparin-binding growth 
factors that have been shown to be involved in the fibrotic process and include vascular endothelial 
growth factor (VEGF) isoforms 165, 189 and 206, epidermal growth factor (EGF), transforming growth 
factor (TGF) α, connective tissue growth factor and hepatocyte growth factor (HGF) [6, 21]. Fine 
structural changes in the HS chains on perlecan can control growth factor signaling. For example, FGF1 
signals when complexed with endothelial cell derived perlecan HS but not smooth muscle cell derived 
perlecan HS [13]. Additionally, cells have the ability to dynamically change the structure of their 
glycosaminoglycan chains as a result of the microenvironment [22] enabling temporal control over 
heparin-binding growth factor activities. The FGF2/perlecan complex is important in specifying the 
spatial distribution of the growth factor while degradation of perlecan destabilizes the complex causing 
FGF2 to lose its defined localization [23] in the ECM enabling it to interact with the syndecan and 
glypican families of cell surface HS proteoglycans [24]. The HS chains that decorate perlecan modulate 
the activity of mitogenic growth factors that support the proliferation of a wide variety of cell types 
including those involved in fibrosis [25-28]. At high cell densities in culture, the proliferation of many 
mesenchymal cell types was reduced by perlecan [25, 29, 30], suggesting that the role of perlecan in 
these situations is complex and not well understood.  
 
1.2.3 Enzymatic regulation by heparanase and sulfatases 
The activity of heparin binding growth factors can be affected by the action of HS modifying enzymes 
including heparanase and the sulfatases. Heparanase cleaves HS both on the cell surface and in the 
basement membrane and has been shown to modulate FGF signaling [31, 32]. Heparanase expression 
is reduced during liver fibrosis and increased in atherosclerosis [14, 17, 33-35]. Sulfatases (SULF)-1 
and -2 selectively remove 6-O-sulfate mainly from trisulfated disaccharide units (IdoA2S-GlcNS6S) 
within S-domains of heparin/HS, where many growth factors, including FGFs, bind. Pretreatment of 
heparin with SULF-2 has been shown to inhibit the binding of many heparin binding growth factors while 
treatment of complexes formed between heparin and growth factors can be released by treatment with 
SULF-2 [36]. In addition, SULF-1 inhibits growth factor binding to its receptor [37]. Interestingly, both 
SULF-1 and -2 are regulated by transforming growth factor (TGF)-β1 and are reported to be upregulated 
in pulmonary fibrosis [38]. Together these studies suggest a role for HS modifying enzymes in the 
regulation of growth factor signaling events in fibrosis. 
 
1.2.4 Roles of the protein core 
Perlecan possesses an α2β1 integrin binding site in domain V that mediates cell adhesion, while 
other putative cell adhesion sites reside in domains III and IV [13, 39, 40]. In addition, domain III of 
mouse perlecan contains an RGD sequence that may interact with integrins [41]. Perlecan can support 
the proliferation of a wide variety of cell types including those involved in fibrosis [25-28]. Perlecan can 
also be anti-proliferative for cell types such as smooth muscle cells (SMCs) via both HS and protein 
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core, particularly domain III [13, 42], that is mediated by the tumor suppressor PTEN [43]. Perlecan can 
also bind some growth factors via its protein core including platelet-derived growth factor (PDGF) to 
domain III [44] and keratinocyte growth factor (also known as FGF7) to both domains III and V [45]. Low 
density lipoprotein (LDL) binds to perlecan domain II and this binding is modulated by HS [35, 46]. 
Proteolytic processing of perlecan by chymase, MMPs, and cathepsins which can cleave in perlecan 
domain IV has been reported to generate perlecan fragments encompassing endorepellin [10], which 
is a recombinant form of perlecan domain V named due to its anti-angiogenic activities [47, 48]. 
Although endorepellin contains a glycosaminoglycan attachment site in its protein sequence it is devoid 
of a glycosaminoglycan chain [47], thus its activities are ascribed to the protein core. Endorepellin can 
be cleaved by BMP1/Tolloid-like proteases and cathepsin L to release the laminin G-like domain (LG)3 
region that includes the α2β1 integrin binding site [49, 50]. Inflammatory cells including mast cells 
produce alternatively spliced forms of perlecan with a relative increase in the amount of transcripts 
corresponding to domain V [51]. Together the various roles of the perlecan protein core suggest that 
perlecan may exert its roles in fibrosis through both the parent molecule and biologically active 
fragments. 
 
1.2.5 Roles in ECM organization 
Perlecan is an essential molecule in tissue and organ development with roles in ECM stabilization 
and the maintenance of the functional status of mature connective tissues [52]. Perlecan interacts with 
a diverse range of ECM components including fibronectin, laminin and many of the collagens 
coordinating the organization of a diverse array of structural glycoproteins and ECM proteins [17, 53].  
For example, perlecan assists in collagen fibrillogenesis, largely through its pendant glycosaminoglycan 
chains [54, 55].  
 
 
2 Manifestations of fibrosis and the fundamental roles of perlecan 
Fibrosis can affect a number of different tissues and organs in the body including the lung, liver, 
skin, kidney, neural and vascular tissues. The fibrogenic response involves several phases of cell-based 
processes such as fibroblast and immune cell activation, immune cell infiltration and delayed apoptosis 
resulting in the accumulation of ECM, which is the accepted hallmark of the condition. The many roles 
of perlecan described above suggest that it has important roles to play in both modulating and promoting 
fibrogenesis. The roles of perlecan in fibrogenesis are reviewed in the following sections drawing upon 
evidence in the literature of tissue-specific examples. A summary of the known roles of perlecan and 
their impact on fibrogenesis are summarized in Fig. 1. 
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Fig. 1. Roles of perlecan in fibrogenesis mediated by both its protein core and glycosaminoglycan chains. 
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A key event in the initiation of fibrosis is the activation of fibrocyte and fibroblast cells and their trans-
differentiation to myofibroblastic-like cells that express α-smooth muscle actin (α-SMA). Interestingly, 
the activation of fibroblasts is not unique to fibrosis as it occurs in cancer, decidualization and infection 
[56-58]. The net accumulation of ECM in injured tissues results from the increased synthesis of ECM 
components including collagen types I and III, perlecan and laminins by cells [59]. Cells that infiltrate 
the injured site, including circulating inflammatory cells and fibrocytes, may also contribute to the 
synthesis of ECM locally; for example, monocyte-derived macrophages express perlecan in response 
to hypoxia mediated via the HIF-1α pathway [60] while macrophages and granulocytes have also been 
shown to produce perlecan [10, 60]. Another example is the infiltration of mesenchymal stem cells and 
pericytes that potentially contribute to lung fibrosis that express the PDGF receptor α as well as 
fibrocytes of bone marrow origin [61] that home to sites of remodeling via CXC chemokine ligand 
(CXCL)12 and CXCR4 involving HS [62]. In ECM remodeling and repair, the myofibroblasts and 
fibroblasts are cleared through apoptosis [63]. However, during fibrosis the wound healing phase fails 
to terminate due to the lack of apoptosis of these cells and it has been hypothesized that the C-terminal 
fragment of perlecan directs cell apoptosis [64, 65].  
Perlecan is involved in the generation of chemotactic growth factor and morphogen gradients which 
recruit cells to sites of ECM remodeling, primarily through interactions of the cytokines with its HS chains 
[66-70] but also including interactions of growth factors with its protein core [45]. Numerous cytokines 
including CC chemokine ligand (CCL) -2, -3 and -5 and CXCL-1, -8 (also known as interleukin (IL)-8), -
9 and -10 and -12 (also known as stromal cell derived factor 1α) bind HS/heparin [71-78] and their 
gradients in tissues are likely to be affected by the structure of the perlecan HS chains. These factors 
promote the migration of fibrogenic cells to the site of injury thereby amplifying inflammation [79]. This 
selective action suggests that perlecan may be involved in recruiting cell types that contribute to the 
organization of provisional matrix during tissue repair, and not those with a profibrotic phenotype, which 
would limit fibrosis [80].    
TGFβ1 is one of the major cytokines involved in upregulating perlecan expression and it is expressed 
by many of the cell types involved in fibrogenesis in tissues including hepatic stellate cells (HSCs), 
fibroblasts, astrocytes and microglia, specialized brain macrophages [81-84]. The latent form of TGFβ1 
is activated by plasmin that in turn upregulates perlecan expression [85, 86]. There is also evidence of 
TGFβ1 regulating perlecan expression when endothelial cells are plated at high density, which may 
promote the repair of the injured endothelium in vivo [87].  
Perlecan interacts with type IV collagen and a number of structural proteins to help form the 
basement membranes [88-90]. It assists in collagen fibrillogenesis, largely through its pendant CS 
chains [54], but there is evidence that this may also involve HS-dependent mechanisms [55].  Perlecan 
facilitates the interactions of laminin and collagen in conjunction with proline-arginine-rich end leucine-
rich repeat protein (PRELP), a collagen anchorage small leucine-rich proteoglycan, to create the 
basement membrane present in many tissues including those discussed in more detail in the next 
sections [91, 92].  
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2.1 Lung 
In lung, chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary fibrosis 
(IPF) affect the parenchymal tissue manifesting as a thickening of the subepithelial ECM [93, 94].  While 
both COPD and IPF exhibit a progressive loss of alveolar parenchyma, COPD is an obstructive disease 
with airway inflammation and IPF is a restrictive disease [95]. The major ECM producing cells are 
fibroblasts and myofibroblasts while airway epithelial and SMCs are also involved [94, 96, 97] (Fig. 2A). 
Airway SMCs obtained from donors with COPD showed enhanced perlecan production following 
stimulation with TGFβ1 that was driven by intracellular SMAD activation [86]. Furthermore, this study 
demonstrated that COPD airway SMCs adhered to perlecan via epitopes in domains IV and V [86]. 
Interestingly, the ECM is degraded in the alveoli and excessive deposition in the bronchi and 
bronchioles that is correlated with differences in the fibroblast morphology, proliferation and ECM 
production [98]. Phenotypically different fibroblasts have been reported in central airways and lung 
parenchyma in COPD [99]. Fibroblasts in the parenchymal tissue were more sensitive to TGFβ1 
expression than in the central airways, which resulted in increased VEGF synthesis, proliferation and 
increased the synthesis of perlecan [99, 100]. Fibrotic cells from biopsies taken from patients with 
asthmatic symptoms showed an increased secretion of perlecan in culture media compared to cells 
from normal patients [101]. In addition, cigarette smoke extract increased perlecan expression by COPD 
fibroblasts in vitro, however the mechanisms involved have not been explored [102]. 
In a rat model of bleomycin-induced pulmonary fibrosis, total proteoglycan content was significantly 
increased, including the expression level of perlecan [103]. Furthermore, primary lung fibroblast cultures 
established from rats after bleomycin induction exhibited increased production of perlecan, compared 
with normal lung fibroblasts together with a significant increase in the amount of TGFβ1[104]. Incubation 
with an anti-TGFβ1 antibody inhibited proteoglycan expression in a dose-dependent manner, indicating 
that TGFβ1 was responsible in part for the increase in proteoglycan production in fibrotic cells [104]. 
Nitric oxide has been reported to downregulate perlecan expression in asthmatic lung fibroblasts [105]. 
Fibulin-1 peptides can stimulate the production of perlecan in lung derived airway SMCs and fibroblasts 
from patients with pulmonary fibrosis and COPD [106]. The augmented deposition of cell-associated 
perlecan together with fibronectin modulated by fibulin-1 may enhance fibroblast activity and extend 
fibroblast induced lung remodeling [106].  
The structures of the HS chains decorating perlecan in lung tissue from patients with IPF showed 
increased levels of glycosaminoglycans as well as increased sulfation of the HS in the areas of 
increased matrix deposition linking these changes in glycosaminoglycan structure to the altered growth 
factor activity in fibrosis [107]. Immunohistochemical staining showed co-localization of perlecan and 
the highly sulfated HS, indicating perlecan may be the core protein that harbors these highly sulfated 
HS chains [107]. The altered HS composition in IPF may thus suggest that the ECM landscape in 
fibrosis favors growth factor activity and tissue remodeling [107]. 
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Fig. 2. Schematic of where fibrogenesis occurs and the cell types involved in (A) lung, (B) liver, (C) skin, (D) kidney, (E) neural tissues and (F) blood vessels. 
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2.2 Liver  
Hepatic endothelial cells line the space of Disse, which contains a non-continuous basement 
membrane due to a lack of polymerized laminin, which presumably facilitates the movement of cells 
and blood throughout and across the liver sinusoids (Fig. 2B). Despite the absence of polymerized 
laminin, this discontinuous membrane contained significant amounts of other ECM components 
including collagen, perlecan and fibronectin [2, 24, 108, 109]. In contrast, laminin is present together 
with collagen type IV in classical continuous basement membranes around liver biliary ducts and blood 
vessels [110]. In fibrosis, peri-sinusoidal basement membranes are synthesized and it has been shown 
that these contain laminin and collagen fibrils that are deposited, along with increased perlecan 
expression [2, 85, 108, 110-113]. The production of these basement membrane structures can cause 
functional changes that impact upon the exchange of macromolecules between the endothelial 
sinusoids and hepatocytes in the liver [93, 114, 115]. While perlecan is a major component of the 
perisinusoidal basement membrane in the liver, it along with type XVIII collagen is upregulated in 
fibrosis [2, 116]. 
The primary cells that are responsible for the deposition of the ECM in liver fibrosis are HSCs [4] 
that are resident peri-sinusoidal cells in the subendothelial space residing between the hepatocytes and 
sinusoidal endothelial cells. These cells become activated at sites of injury by factors produced by 
hepatocytes and endothelial cells, as well as infiltrating inflammatory cells including macrophages [117-
121]. Once activated HSCs exhibit increased mitogenic activity in the presence of PDGF-BB, a heparin 
binding growth factor that binds to perlecan HS and signals cells via the Ras-mitogen-activated protein 
kinase (MAPK) pathway via an upregulation of the PDGF-β receptor [17, 29]. The increased production 
and activity of cytokines are required for the continued activation of HSCs, which amplify inflammation 
through the release of neutrophil and monocyte chemo-attractants, such as monocyte chemotactic 
protein 1 (MCP-1) and colony-stimulating factor [122]. This positive feedback system results in an 
accumulation of HSCs and macrophages at the site of injury and it is interesting to note that activated 
HSCs respond to MCP-1 [123] that binds perlecan [124], demonstrating a level of cross talk in the 
system resulting in an accumulation of HSCs at the site.  
Perlecan is upregulated in the periportal parenchyma during chronic cholestatic disease [24] and 
there is an increase in the HS and CS/dermatan sulfate (DS) content [125, 126] together with an 
upregulation of some of the enzymes involved in sulfate modification of HS including the 6-O-
sulfotransferases and glucosamine 3-O-sulfotransferase 1 enzymes involved in producing heparin-like 
sequences [126]. This supports the hypothesis that an increased abundance of these highly sulfated 
glycosaminoglycan sequences promote both collagen fibrillogenesis and laminin polymerization [54, 
55, 127].  
Matrix metalloproteinase (MMP) activity is increased in fibrosis, particularly MMP-2,-3 and -9, that 
degrades basement membrane components, including perlecan [94, 128-131], and replace this ECM 
with type I collagen which further activates cell growth and MMP production [132]. MMPs are derived 
from tissue resident cell populations, activated HSCs and Kupffer cells which are specialized liver 
macrophages [133]. 
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In congenital hepatic fibrosis, there is a marked infiltration of mast cells scattered throughout the 
portal structures. These are more abundant than in other chronic liver diseases such as chronic viral 
hepatitis and alcoholic fibrosis [134] suggesting that mast cells might have a specific role in the 
congenital condition. It is tempting to speculate that it might involve the expression of the shorter forms 
of perlecan previously shown to be produced by mast cells [10, 51] which are produced by the actions 
of proteases secreted by mast cells including chymase or are a result of mRNA splicing and processing 
as shown for the mast cell line, HMC-1 [10].  
 
2.3 Skin 
The initiation of fibrosis in skin requires the epithelial cells in the epidermis to undergo an epithelial 
to mesenchymal transition, which converts the cell into an ECM expressing cell [94] (Fig. 2C). Perlecan 
is expressed throughout the epidermis and dermis of skin with a peri-cellular pattern with little 
demonstrable in the epithelial basement membrane. Aged keratinocytes have been reported to be 
perlecan deficient and were unable to form a multilayered epidermis with  defects in cell proliferation 
and differentiation, suggesting that perlecan is a key modulator of cell proliferation [135]. Endorepellin 
has cell-signaling roles and was implicated as a key fibrogenic mediator [64]. Apoptosis of endothelial 
cells induces ECM proteolysis, and subsequently acts through phosphoinositide 3-kinase (PI3K) to 
prevent apoptosis in fibroblasts [65], implicating C-terminal fragments of perlecan in delaying fibroblast 
apoptosis. However, an increase in collagen secretion was not observed in response to endorepellin 
alone, indicating that additional apoptotic factors must act in a coordinated fashion to induce all features 
of myofibroblast differentiation [64]. Interestingly, human fibroblasts derived from sclerodermia skin 
lesions were more sensitive to the action of endorepellin than fibroblasts derived from healthy control 
skin [64], indicating a disease specific response to perlecan signaling. 
 
2.4 Kidney 
Renal fibrosis occurs in chronic nephropathies, leading to changes to the tubular and glomerular 
basement membranes and interstitial ECM resulting in decreased kidney function and eventually failure 
[136] (Fig. 2D). Kidney infections, toxins, mechanical obstruction, immune complexes resulting from 
autoimmune diseases or chronic infections and genetic disorders lead to cellular injury while type-2 
diabetes mellitus and ischemic/hypertensive nephropathy also contribute to kidney fibrogenesis [137]. 
Fibrotic changes in the kidney can also be caused by genetic mutations such as Denys-Drash syndrome 
from mutations in the WT1 gene that causes an initial decrease in perlecan expression that is later 
reversed and increases along with collagen type IV, laminin, fibronectin and tenascin and results in 
mesangial sclerosis [96]. In the kidney, the major HS proteoglycan in the glomerular basement 
membrane is agrin [138] while perlecan plays a major role in filtration in the glomeruli [139] and has 
been correlated with a slower progression of IgA nephropathy [140]. Decreased amounts of perlecan 
have been shown in animal models of diabetic nephropathy as well as in diabetic patients [141]. 
Perlecan is also decreased in glomerular nephritis and IgA nephropathy whereas biglycan and decorin 
are both up regulated with a concomitant upregulation of TGFβ suggesting that a positive autocrine 
loop plays a major role in the expansion of the mesangial matrix [140]. Further, in an animal model of 
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diabetic nephropathy streptozotocin elevated levels of TGFβ and was a major factor in the up-regulation 
of tissue fibrosis [142]. An increase in collagen types I, III and IV and fibronectin accompanied the 
decreased expression of perlecan in this model [143]. 
In sclerotic lesions of focal glomerulosclerosis in a rat renal transplant model, an induction of 
perlecan expression in the glomerular basement membrane was detected compared with its expression 
in control kidneys [144]. The observed induction of perlecan expression was also observed in the 
interstitium in a capillary-like pattern. Kidney allografts also presented extensive lymphangiogenesis, 
associated with induced perlecan expression underneath the lymphatic endothelium. The magnitude of 
lymphangiogenesis and perlecan expression both correlated with severity of interstitial fibrosis and 
impaired graft function [144]. 
 
2.5 Glial scarring in neural tissues 
Glial scarring can arise in neural tissues that have undergone physical injury due to trauma including 
injury to the spinal cord or an hypoxic insult as a result of ischemia or cerebral stroke. In neural tissues, 
astrocytes, oligodendrocytes, Schwann cells and microglia, specialized brain macrophages, are the 
major cell types involved in the production of ECM components and assembly of myelin [145, 146] (Fig. 
2E). The microglia and astrocytes have major roles in fibrosis after becoming activated in response to 
the release of inflammatory cytokines such as IL-1β and TGFβ [145, 146]. These cytokines cause 
further release of proinflammatory cytokines and an upregulation of ECM molecules, most notably CS 
lectican proteoglycans including aggrecan, versican, neurocan, brevican [147] and phosphacan [145, 
146]. Perlecan has a central role in the developing brain by regulating neurogenesis through the control 
of neural cell position and phenotype in regions of the developing brain [148, 149]. 
The CS proteoglycans present in the glial scar surrounding the lesion site prevent neurite outgrowth 
in vitro and nerve regeneration in vivo [150]. A recent transcriptomic analysis of astrocytes stimulated 
with IL-1β showed no evidence of upregulation of any of the CS proteoglycan genes suggesting that 
they were not the only proteoglycans in the glial scar [151].  Rat cortical astrocytes were shown to 
produce more HS than CS in culture with a relatively higher content of unsubstituted glucosamine 
disaccharides. The glycosaminoglycan chains of higher negative charge were more effective at 
stimulating nerve growth factor (NGF) signaling in PC12 cells but the protein core to which the HS was 
attached was not investigated [152]. The heparin binding domain of laminin is responsible for neurite 
outgrowth together with NGF [127] implicating HS proteoglycans in this process. The C-terminal domain 
V region of perlecan delayed the onset of glial scarring in rat models by decreasing the expression of 
neurocan and phosphacan and stimulating the activity of NGF [153]. These data suggest that the 
balance between CS and HS proteoglycans in the ECM and the alteration in this balance changes the 
nature of the surrounding environment, which can either inhibit or stimulate neurite outgrowth and nerve 
regeneration [154]. 
While the laminin-like G domain (LG)3 fragment, as yet, has not been associated with the formation 
of glial scarring, mice deficient of neural/glial antigen 2 (NG2)/chondroitin sulfate proteoglycan 4 
(CSPG4) had a reduced amount of glial scarring and were more permissive to axonal regrowth [155]. 
Interestingly these animals had a similar phenotype to the progranulin deficient animals [155]. 
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Progranulin is a neuroprotective molecule [156] that binds to the C-terminal region of perlecan and 
specifically to the first two laminin like repeats LG1 and LG2 [157]. A recent study indicated that the C-
terminal region of perlecan binds to CSPG4 [158] and it is tempting to speculate that this binding 
involves an intermediate interaction with progranulin. Interestingly, this same C-terminal region of 
perlecan is neuroprotective and pro-angiogenic in a rat ischemic model [159].   
 
2.6 Blood vessels and vascular tissues 
Atherosclerosis is characterized by intimal thickening due to an over production of ECM and lipid 
accumulation in the intima as well as macrophage activation and foam cell formation [160, 161] (Fig. 
2F). Monocyte recruitment, retention and differentiation play a central role in the development of 
atherosclerosis [161] and removal of HS increased the association of monocytes with the subendothelial 
matrix [35] suggesting that HS may inhibit monocyte interactions with the ECM by inhibiting cell-surface 
integrin interactions [162, 163]. The initial activation of SMCs after arterial injury is coupled with a 
decrease in the expression of laminin and basement membrane-like structures, whereas fibronectin 
accumulates around proliferating cells in the arterial media and intima [164]. Perlecan can act directly 
on fibrocyte-like cell activation through promotion of cell adhesion or indirectly via binding and 
potentiating the signaling of growth factors and cytokines involved in cell activation and proliferation 
[165]. Non-human primates fed a diet to induce hypercholesterolemia demonstrated atherosclerotic 
lesions with perlecan associated with the media in normal vessels and early stages of lesion formation 
and was prominent in the SMC matrix near the plaque core of more advanced lesions [166]. These 
observations indicate that basement membrane components, including perlecan, may take part in the 
regulation of the differentiated state of ECM producing cells [167]. 
The progression and organization of the developing plaque in blood vessels, including migration and 
proliferation of SMCs into the intima, results in the secretion of collagen and the formation of a fibrous 
cap that surrounds the lipid rich core of the plaque. Perlecan is thought to have pro-atherogenic effects 
by retaining lipoproteins in the matrix in the early phase of atherosclerosis [46, 168]. Perlecan supports 
low density lipoprotein (LDL) sequestration via its protein core, notably domain II, while HS modulates 
this binding [35, 46], a key effect in the progression of atherogenesis.  
Vascular SMC proliferation occurs via FGF2 and suggests a role for perlecan in the downregulation 
of the FGF2 mediated proliferative response as demonstrated by the HS chains that decorate SMC 
derived perlecan did not potentiate the growth signal of FGFs [13]. Removal of HS, through the action 
of the HS degrading enzyme heparanase [169], from late vascular lesion explants supported the 
proliferation of neointimal SMCs and rendered them responsive to PDGF [17, 170]. FGF2 is also 
induced by PDGF treatment of SMCs, further supporting the role of FGF2 in the proliferation of SMCs 
[171]. While perlecan is often thought of as a pro-atherogenic molecule [172], vascular SMC activation 
and proliferation is inhibited by perlecan [170, 173, 174] and it is the lack of perlecan expression in early 
initiation of atherosclerosis that enables SMC activation, proliferation and ECM synthesis [170]. When 
SMCs are present in high density, thrombin can promote perlecan synthesis [175, 176] and may act in 
concert with mechanical strain and angiotensin II [177-179]. This suggests that perlecan expression is 
tightly linked to limiting SMC activation and proliferation. In the vasculature this suppression of SMC 
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activation is mediated by thrombin and factor Xa [177]. The mechanisms by which perlecan is anti-
proliferative for vascular SMCs is via both HS and protein core, particularly domain III [13, 42], that is 
mediated by the tumor suppressor phosphatase and tensin homolog (PTEN), which inhibits growth 
factor receptor signaling [43]. Furthermore, perlecan has been implicated in inhibiting growth of vascular 
SMCs via Oct-1, a member of a family of transcription factors involved in cell growth processes and 
suggest that breakdown of the basement membrane and loss of interaction with perlecan activates cells 
from their quiescent state [173]. Plaque development is also attributed to the HS chains on perlecan as 
demonstrated by mice lacking HS in the N-terminal domain of perlecan on an ApoE-deficient 
background exhibit reduced plaque development [172]. Thus the ability of perlecan to suppress SMC 
proliferation may contribute to plaque instability as it is the SMCs that produce the fibrous cap that 
stabilizes the lipid plaques.  
Cadmium is an environmental risk factor for atherosclerosis and has been found to induce changes 
in the expression of endothelial perlecan with markedly shorter HS chains that were able to stimulate 
the proliferation of vascular SMCs in the presence of FGF2 [180]. Heparin has also been reported to 
upregulate perlecan expression in vascular SMCs [42] and hypothesized to promote FGF2 signaling. 
Perlecan expression is increased in late stages of atherosclerosis and modulated by apolipoprotein E 
(apoE) [59, 174] as demonstrated by reduced perlecan expression in apoE deficient mice [160]. A 
murine model of atherosclerosis exhibited enhanced perlecan expression in apoE deficient mice fed a 
chow diet and was expressed in both early and advanced plaques [181]. Nitric oxide may be an 
important intermediate signaling molecule in the induction of perlecan by apoE in SMCs as both are 
required for the modulation of SMC proliferation [174]. 
Myeloperoxidase and peroxynitrous acid released from activated leukocytes selectively degrade the 
core protein of perlecan [182, 183]. The precise degradation site(s) on the core protein await 
identification however, there is evidence for the presence of peroxynitrite-modified perlecan fragments 
in human atherosclerotic lesions [184]. Proteolytic processing of perlecan by chymase, MMPs, and 
cathepsins which can cleave in perlecan domain IV has been reported to generate perlecan fragments 
encompassing endorepellin [47]. Endothelial cell apoptosis triggers a caspase-dependent release of 
the LG3 containing fragment of perlecan suggesting that proteases are responsible for the cleavage of 
perlecan to release this bioactive fragment. This fragment supports the proliferation of vascular SMCs 
and fibroblasts and inhibits their apoptosis [185] through PI3K [65], whilst increasing the expression of 
αSMA through OI3K and collagen types I and III expression in these cells [49, 63, 64]. Interestingly, the 
EGF peptide motif in perlecan domain V together with 4-sulfated CS could replicate this inhibition of 
apoptosis of fibroblasts and vascular SMC [64]. However, an increase in collagen secretion was not 
observed in response to endorepellin alone, indicating that additional apoptotic factors act coordinately 
to induce all features of myofibroblast differentiation [185].  
Endorepellin interacts with VEGF receptor 2 providing evidence for its ability to control cell adhesion 
and VEGF-mediated mitogenic activities [186]. The C-terminal domain V of perlecan has either anti-
angiogenic [187, 188] or angiogenic [10, 15] activities in line with the action of the parent molecule. 
Endorepellin has been shown to be anti-angiogenic when added to cultures of endothelial cells by either 
interfering with the interactions between VEGF receptor 2 and the LG1/2 regions in domain V [189] or 
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sterically competing with the α2β1 integrin mechanism of attachment in domain V [39]. Endorepellin 
binds to the N-terminal fragment of type XVIII collagen, known as endostatin, where it counteracts its 
anti-angiogenic activities [47].  
Interestingly, TGFβ is upregulated during the initiation of early atherosclerosis when perlecan 
expression is downregulated, potentially by PDGF that decreases perlecan expression in the 
vasculature [190], suggesting that in the vasculature, perlecan expression is regulated independently 
of TGFβ expression [191]. Concomitant with this decrease in perlecan expression is an increase in the 
levels of CS/DS proteoglycans [160]. Oxidized LDL and lysolecithin, a product of LDL oxidation, both 
decrease endothelial HS proteoglycan expression [35]. While the mechanism is unclear, activation of 
signal transducer and activator of transcription 1 (STAT1) are key signaling molecules involved in 
inhibition of perlecan transcription by oxidants and inflammatory cytokines [35].  
Restenosis is a scarring that occurs in the vasculature following a vascular intervention and involves 
a change in phenotype of the quiescent contractile SMCs to proliferate and produce ECM [192]. This is 
accompanied by a downregulation of their contractile proteins, which is in contrast to fibroblasts in 
fibrosis which upregulate αSMA to become myofibroblasts [193]. Perlecan expression has been 
reported to be low in uninjured blood vessels and immediately following injury which corresponded to 
maximal SMC proliferation, while perlecan has been reported to increase later in advanced lesions that 
coincided with an arrest of SMC proliferation [170]. Interestingly, heparinase treatment promoted SMC 
growth [170] suggesting that the temporal expression of perlecan is important for fibrogenesis.  
The length and sulfation pattern of perlecan HS chains are cell type specific [194], and it is therefore 
likely that these features play a role in the tissue-specific functions of perlecan. Deletion of the 
glycosaminoglycan attachment sites in domain I of mouse perlecan supported the proliferation of SMCs 
following flow cessation of the carotid artery [195] further supporting the role of both the HS and perlecan 
protein core in the modulation of SMC activation and proliferation. In a separate study, HS 
proteoglycans were more effective in inhibiting neointima formation in a rabbit model of restenosis than 
heparin [196] supporting the synergistic role of HS together with the perlecan protein core. These 
studies indicate that during tissue remodeling perlecan promotes desirable cell proliferation whilst 
simultaneously inhibiting undesirable proliferation activities of SMCs. 
 
 
3. Therapies for fibrosis that alter perlecan expression 
While therapies exist which delay fibrogenesis, the contribution of these treatments to the structure 
or abundance of perlecan in fibrosis is less clear. Of the fibrosis treatments explored, sulodexide, a 
mixture of non-anticoagulant low molecular weight heparin/HS and DS, has been shown to increase 
perlecan expression in a rat model of diabetic nephropathy, whilst the expression of collagens I and IV 
decreased suggesting that TGFβ may be controlled by interacting with the glycosaminoglycans [143]. 
Additionally, in vitro culture of tubular cells treated with sulodexide reduced expression of αSMA, 
heparanase-1 and MMP9 suggesting that this treatment inhibited the epithelial-mesenchymal transition 
characteristic of fibrosis [197]. Additionally, perlecan expression is upregulated via treatment of murine 
atherosclerosis with telmisartan, an angiotensin II receptor antagonist [198]. 
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 With the concept of the multifaceted roles of perlecan in fibrosis, the effect of the following fibrosis 
treatments warrant further investigation for their effect on perlecan expression. Nintedanib, a tyrosine 
kinase inhibitor, is approved for the treatment of IPF [199]. It inhibits a variety of receptors including the 
PDGF receptor, VEGF receptors 1 and 2, and FGF receptors 1–3 [200]  and affects the binding partners 
for perlecan that are involved in cell proliferation in fibrosis, although analysis of the effect on perlecan 
expression has not been examined. Nintedanib inhibits the progression of processes in fibrosis 
including the migration of fibroblasts, their transformation into myofibroblasts and the deposition of 
extracellular matrix [201, 202] thus it is possible to speculate that this treatment affects perlecan 
expression. Through a similar approach, sorafenib targets the PDGF receptor and is effective in 
reducing fibrosis in animal models of liver fibrosis [203] and many also affect perlecan expression.  
Adenoviral vectors expressing an antisense mRNA of the PDGF β-chain delivered to an animal 
model of induced liver fibrogenesis down-regulated endogenous PDGF β -chain expression [204, 205], 
which is likely to lead to increased perlecan expression [190] with a positive outcome for modulating 
the progression of fibrosis. Pirfenidone inhibits TGFβ1 stimulated collagen expression [206] and in vitro 
experiments have shown that it can inhibit the proliferation of HSCs and lung fibroblasts [207-209] and 
is thus worthy of further exploration for its effect on perlecan expression. 
Statins are effective in lowering LDL cholesterol [210] and also reduced plaque volume when used 
at high dose [210]. ApoE deficient mice treated with statins also display reduced plaque volume with 
increased decorin and biglycan expression and a more condensed collagen rich ECM, however 
perlecan expression was not altered in these mice [211] even though it has a major role in LDL retention 
and has been shown to modulate HS proteoglycan expression [35]. The renin-angiotensin system 
(RAS) is a central regulatory system for cardiovascular function and critically connected to 
atherosclerosis and mediated by angiotensin II. RAS blockade has been shown to attenuate the 
progression of atherosclerotic lesions in animals and is thus a promising therapy for human 
cardiovascular diseases [191]. A novel perlecan-inducing compound, RUS310, is a potent inhibitor of 
SMC activity and has been trialed for the treatment of in-stent restenosis [212]. So far this compound 
has not been trialed for the treatment of fibrosis, but may be a rewarding approach to modulate perlecan 
expression.  
 
 
4. Final Considerations 
The literature provides ample evidence for the roles of perlecan in controlling / modulating 
fibrogenesis (Fig. 1). Perlecan has key roles in promoting tissue repair whilst limiting damaging fibrosis 
even though many of the tissue repair activities can also contribute to fibrogenesis if not resolved in a 
timely fashion (Fig. 3). The anti-fibrotic activities of perlecan are mediated through modulating cell 
adhesion, proliferation and migration of key inflammatory and ECM producing cells.  In contrast, 
perlecan contributes to fibrogenesis through growth factor binding and signaling, LDL binding, ECM 
interactions and activities of the C-terminal region of perlecan that inhibit the apoptosis of fibroblasts. 
These multifaceted roles of perlecan suggest that it plays a role in each phase of fibrogenesis, with 
particularly important roles in modulating the activity of growth factors, chemokines and cytokines for 
17 
 
cell activation, infiltration and proliferation. These activities can be attributed to either the 
glycosaminoglycan or protein core components of perlecan. The glycosaminoglycan chains change 
dynamically as a result of changes in the microenvironment enabling temporal and spatial control over 
growth factor, chemokine and cytokine activity. While the precise mechanisms involved in the roles of 
perlecan involved in fibrogenesis remain unclear, the current evidence suggests that it is an important 
candidate worthy of further development of more effective treatments for fibrosis.  
 
 
 
Fig. 3. The anti- and pro-fibrotic activities of perlecan that are open to therapeutic manipulation. 
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